{"nctId":"NCT00004054","briefTitle":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","startDateStruct":{"date":"2000-01"},"conditions":["Prostate Cancer"],"count":397,"armGroups":[{"label":"Hormones and RT","type":"EXPERIMENTAL","interventionNames":["Drug: bicalutamide","Drug: flutamide","Drug: Luteinizing hormone releasing hormone [LHRH] agonist","Radiation: Radiation therapy"]},{"label":"Hormones and RT plus Chemotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: bicalutamide","Drug: estramustine phosphate sodium","Drug: etoposide","Drug: flutamide","Drug: paclitaxel","Radiation: Radiation therapy","Drug: warfarin"]}],"interventions":[{"name":"bicalutamide","otherNames":["Casodex"]},{"name":"estramustine phosphate sodium","otherNames":[]},{"name":"etoposide","otherNames":[]},{"name":"flutamide","otherNames":["Eulexin"]},{"name":"paclitaxel","otherNames":[]},{"name":"Luteinizing hormone releasing hormone [LHRH] agonist","otherNames":[]},{"name":"Radiation therapy","otherNames":[]},{"name":"warfarin","otherNames":["Coumadin"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically proven prostate cancer at high risk for relapse as determined by either of the following:\n\n  * Prostate-specific antigen (PSA) 20-100 ng/mL and Gleason score at least 7 (any T stage)\n  * Clinical stage at least T2, Gleason score at least 8, and PSA no greater than 100 ng/mL\n* Negative lymph nodes\n* No metastatic disease\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* Over 18\n\nPerformance status:\n\n* Zubrod 0 or 1\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* White blood cell (WBC) count of at least 3,000/mm\\^3\n* Platelet count at least 130,000/mm\\^3\n* Hemoglobin at least 11.4 g/dL\n\nHepatic:\n\n* Aspartate aminotransferase (AST) no greater than 2 times upper limit of normal\n\nRenal:\n\n* Creatinine no greater than 2.5 mg/dL\n\nOther:\n\n* No other invasive cancer within the past 5 years except superficial nonmelanomatous skin cancer\n* No major medical or psychiatric illness that would preclude study participation\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* At least 5 years since prior chemotherapy\n\nEndocrine therapy:\n\n* At least 60 days since prior finasteride for prostatic hypertrophy\n* At least 90 days since prior testosterone\n* No more than 30 days since initiation of prior pharmacologic androgen ablation for prostate cancer\n\nRadiotherapy:\n\n* No prior pelvic radiotherapy\n* No concurrent intensity-modulated radiotherapy\n\nSurgery:\n\n* No prior radical prostatectomy\n* No prior cryosurgery for prostate cancer\n* No prior orchiectomy","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (5-year Rate Reported)","description":"Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 5 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.9","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Biochemical Failure at 5 Years","description":"Biochemical failure uses the American Society for Radiation Oncology (ASTRO) definition of prostate-specific antigen (PSA) rises on three consecutive occasions, with biochemical failure date being midway between the last non-rising PSA and the first rise in PSA. Time to biochemical failure is defined as time from randomization to biochemical failure, last known follow-up (censored), or death (competing risk). Biochemical failure rates are estimated using the cumulative incidence method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Local Progression at 5 Years","description":"Local progression is defined as documented clinical local and/or regional progression. Time to local progression is defined as time from randomization to local progression, last known follow-up (censored), or death (competing risk). Local progression rates are estimated using the cumulative incidence method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Distant Metastasis at Five Years","description":"Distant metastasis (DM) is defined as documented metastatic disease. Time to distant metastasis is defined as time from randomization to distant metastatic disease, last known follow-up (censored), or death (competing risk). Distant metastasis rates are estimated using the cumulative incidence method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease-free Survival Rate at 5 Years","description":"Disease-free survival (DFS) was measured from the date of randomization to the date of documentation of progression (local, distant, biochemical failure), death, or last follow-up (censored). The Kaplan-Meier method was used to estimate DFS rates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1","spread":null},{"groupId":"OG001","value":"42.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":197},"commonTop":["Menopausal symptoms","Urinary frequency","Impotence","Late RT Toxicity: Bladder: NOS","Hemoglobin decreased"]}}}